2025 Q4 -tulosraportti
Vain PDF
31 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 55 | - | - | ||
| 3 950 | - | - | ||
| 50 | - | - | ||
| 10 000 | - | - | ||
| 9 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·8 min sittenThe ASGCT presentations have, in my opinion, more clearly moved the Circio case from "high expression" to what Big Pharma actually cares most about: significant dose reduction, better safety margin, and lower treatment cost in AAV gene therapy.
34 min sitten34 min sittenThe power of circular RNA. More circular RNA at ASGCT, abstract https://distribution.us.m-anage.com/from.storage?image=Kn0KAtCjscVNEYTvg0_NVyDmqYH4nOiZ0PoDsZiXFgrGMRTL5OIsNl3NVnleDe7r0 , Strand Therapeutics on X https://x.com/StrandTx/status/2055271986285117628?s=20 Summary: Boston biotech Strand Therapeutics Inc. is also a pioneer developing circRNA based technologies for the in vivo programming of CAR Ts. At ASGCT, the company presented data of their STX-005 strategy for autoimmune disease and hematological malignancies, including refractory autoimmune conditions, lymphomas and multiple myelomas. “We are trying to convert this therapy, recreate all the wonderful clinical efficacy in an off the shelf format using a lipid nanoparticle and a circular RNA inside the lipid nanoparticle that expresses the chimeric antigen receptor,” Tasuku Kitada told BioWorld. Kitada is the co-founder, board director, president, and head of R&D at Strand Therapeutics. STX-005 combines three layers of engineering, the delivery vector, the circular RNA and the CAR receptor itself. However, this design includes a novel component that solves of target activation. The foundation is a targeted LNP capable of recognizing and transfecting CD8 lymphocytes inside the body. Inside the LNP travels a circular RNA that expresses the CAR. This RNA is deeply optimized to increase translation about tenfold compared with natural sequences and uses codon optimization specifically for circRNA. The goal is to achieve high and durable protein levels without relying on integrative vectors. In addition, STX-005 incorporates a Signallock system based on endogenous microRNA sensors. The circRNA contains sequences that allow microRNAs to modulate it or enable unwanted cells to degrade it, while in T cells it remains intact and functional. This restricts CAR expression to lymphocytes and prevents activity in tissues such as liver, lung or heart. “We are using what we call our Signallock technology, that technology where the signal is the key, and we're blocking it so that only when the signal is delivered to the target cells, the immune cells, we unlock the signal and express protein. And the reason we're doing that, for instance for chimeric antigen receptor T cell therapy, is that you want to express it in the T cells,” Kitada explained. “And the reason that's important is that if you think about a potential immune response that you can trigger inside the patient's body against the chimeric antigen receptors, you really want to limit the protein expression to the cells where you need to express it,” he remarked. The design uses costimulatory and activation domains that increase the efficacy of the CAR. “Our circular RNA is longer lasting because it's circular and because of all the optimizations. … However, it's still transient. It eventually goes away and gets degraded. So, you can optimize what's called the costimulatory domain or activation domain. And there are a lot of engineering tricks that you can incorporate into the chimeric antigen receptor so that it's optimal for this kind of transient mRNA or circular RNA based expression approach,” he said. The results show clear improvements in every model evaluated. In resting human T cells, the optimized circRNAs increase CAR expression sixfold on day 1 and twofold on day 7. The redesigned CAR also performs better, showing a fivefold increase in surface expression after antigen contact and a similar boost in cytotoxic activity in vitro. In vivo, the targeted LNP efficiently delivers the payload, reaching up to 90 percent expression in humanized mice and causing up to 90 percent B cell depletion with a single dose. The Signallock system also works as intended, keeping expression restricted to T cells. In non-human primates, two intravenous doses lead to up to 98 percent B cell depletion in blood, spleen, and lymph nodes. Overall, the combination of the optimized circRNA, the targeted LNP and the CAR design adapted for transient expression produces strong activity across models while maintaining cell type specificity. “You want that transient but deep depletion of the B cells. … The pathogenic B cells are depleted, and then you recover, and you don't have any risk of cancer. So that's one way to think about it,” he said. “Unlike lentiviral integration, we can redose the lipid nanoparticle in patients. … By repeat dosing, you can treat the patient's cancer without the risk of oncogenesis via integration. So, there are a lot of ways to think about this. I think we are still in very early days.” Their next steps include completing additional experiments this year to select the final design, further optimizing the nanoparticle, the circRNA and the CAR, and nominating a development candidate in early 2027, with initial indications in hematologic cancers and potential extensions into autoimmunity (29th Annu Meet Am Soc Gen Cell Ther (ASGCT) (May 11-16, Boston) 2026).·13 min sittenStrand validates circRNA in LNP/in vivo CAR-T. Circio validates circRNA in AAV/gene therapy. Both indicate that the field is moving in the same direction. Strand shows that circRNA can function very strongly in LNP/in vivo CAR-T. Circio shows that circRNA can greatly improve AAV gene therapy. Together, they make the sector more attractive for Big Pharma.
·38 min sittenStop sharing old analyses and data that we've known since February! It's super awkward. ASGCT's presentations have for Circio meant a focus on reduced dosage, thereby improved safety and better economics, which is clearly the big problem with classic mRNA and what Big Pharma craves. But also shown that circVec can potentially be used in all types of tissue/body parts. That they now also have an "ongoing muscle program", as the 4th area, is super exciting. 💰 Now it's just about building relationships and publishing even more, but fortunately we have Erik Wiklund who is a true world champion in that field.
25 min sitten25 min sittenTämä julkaisu on poistettu.
·25 min sittenI also don't have the energy to read up on it, just like sigpig, so if someone would serve it all to me on a silver platter? Because we REALLY don't have the energy to do things ourselves.
·44 min sittenAI finds increased mention in social media and LinkedIn after oral presentation. Also a bit interesting that the topic of conversation around Circio changes character a bit. From AI: There are now clear signs of increasing international visibility around Circio Holding ASA after the ASGCT presentation. Most important new developments: * BiotechTV-interview from ASGCT gets noticeably more spread than previous Circio mentions. CEO Erik Wiklund highlights: * up to 50x increased expression, * lower dosage requirements, * and expansion towards eye, CNS and in vivo CAR-T. * Several biotech profiles on LinkedIn now refer to circRNA as "next-generation therapeutic format", and Circio is mentioned in the same conversations as broader RNA and AAV optimization trends. * It seems that the presentation especially arouses interest because the data addresses some of the biggest challenges in AAV gene therapy: * toxicity at high doses, * production costs, * and insufficient expression. * Analyst Group continues to be among the most positive external voices. They now highlight: * oral selection as third-party validation, * stronger partner relevance, * and that ASGCT can act as a catalyst for licensing dialogues. * It is also noted that Circio now mentions: * existing partnerships, * funding of ~$35M, * and several programs in parallel, which gives a more "platform company" feel than before. * Activity on LinkedIn seems to have increased further since yesterday: * higher engagement on CEO posts, * more biotech-related reposts, * and more international exposure than normal for the company. * There is still relatively little retail hype on open investor forums compared to how much professional discussion is now appearing. It is actually quite interesting, because the attention seems more driven by: * technology, * scientific relevance, * and industrial application, than pure speculation. The most interesting signal right now is perhaps that the discussion gradually shifts from: * "can the technology work?" to: * "how broadly can this be applied and who can become a partner?"·3 min sittenThe BiotechTV interview is more important than usual retail coverage. This is not just a Norwegian stock forum talking to itself. BiotechTV covers American biotech and the ASGCT community. When Circio is featured there, the company becomes more visible to a community that actually understands AAV, RNA, gene therapy, and partner logic.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
31 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 min sittenThe ASGCT presentations have, in my opinion, more clearly moved the Circio case from "high expression" to what Big Pharma actually cares most about: significant dose reduction, better safety margin, and lower treatment cost in AAV gene therapy.
- 34 min sitten34 min sittenThe power of circular RNA. More circular RNA at ASGCT, abstract https://distribution.us.m-anage.com/from.storage?image=Kn0KAtCjscVNEYTvg0_NVyDmqYH4nOiZ0PoDsZiXFgrGMRTL5OIsNl3NVnleDe7r0 , Strand Therapeutics on X https://x.com/StrandTx/status/2055271986285117628?s=20 Summary: Boston biotech Strand Therapeutics Inc. is also a pioneer developing circRNA based technologies for the in vivo programming of CAR Ts. At ASGCT, the company presented data of their STX-005 strategy for autoimmune disease and hematological malignancies, including refractory autoimmune conditions, lymphomas and multiple myelomas. “We are trying to convert this therapy, recreate all the wonderful clinical efficacy in an off the shelf format using a lipid nanoparticle and a circular RNA inside the lipid nanoparticle that expresses the chimeric antigen receptor,” Tasuku Kitada told BioWorld. Kitada is the co-founder, board director, president, and head of R&D at Strand Therapeutics. STX-005 combines three layers of engineering, the delivery vector, the circular RNA and the CAR receptor itself. However, this design includes a novel component that solves of target activation. The foundation is a targeted LNP capable of recognizing and transfecting CD8 lymphocytes inside the body. Inside the LNP travels a circular RNA that expresses the CAR. This RNA is deeply optimized to increase translation about tenfold compared with natural sequences and uses codon optimization specifically for circRNA. The goal is to achieve high and durable protein levels without relying on integrative vectors. In addition, STX-005 incorporates a Signallock system based on endogenous microRNA sensors. The circRNA contains sequences that allow microRNAs to modulate it or enable unwanted cells to degrade it, while in T cells it remains intact and functional. This restricts CAR expression to lymphocytes and prevents activity in tissues such as liver, lung or heart. “We are using what we call our Signallock technology, that technology where the signal is the key, and we're blocking it so that only when the signal is delivered to the target cells, the immune cells, we unlock the signal and express protein. And the reason we're doing that, for instance for chimeric antigen receptor T cell therapy, is that you want to express it in the T cells,” Kitada explained. “And the reason that's important is that if you think about a potential immune response that you can trigger inside the patient's body against the chimeric antigen receptors, you really want to limit the protein expression to the cells where you need to express it,” he remarked. The design uses costimulatory and activation domains that increase the efficacy of the CAR. “Our circular RNA is longer lasting because it's circular and because of all the optimizations. … However, it's still transient. It eventually goes away and gets degraded. So, you can optimize what's called the costimulatory domain or activation domain. And there are a lot of engineering tricks that you can incorporate into the chimeric antigen receptor so that it's optimal for this kind of transient mRNA or circular RNA based expression approach,” he said. The results show clear improvements in every model evaluated. In resting human T cells, the optimized circRNAs increase CAR expression sixfold on day 1 and twofold on day 7. The redesigned CAR also performs better, showing a fivefold increase in surface expression after antigen contact and a similar boost in cytotoxic activity in vitro. In vivo, the targeted LNP efficiently delivers the payload, reaching up to 90 percent expression in humanized mice and causing up to 90 percent B cell depletion with a single dose. The Signallock system also works as intended, keeping expression restricted to T cells. In non-human primates, two intravenous doses lead to up to 98 percent B cell depletion in blood, spleen, and lymph nodes. Overall, the combination of the optimized circRNA, the targeted LNP and the CAR design adapted for transient expression produces strong activity across models while maintaining cell type specificity. “You want that transient but deep depletion of the B cells. … The pathogenic B cells are depleted, and then you recover, and you don't have any risk of cancer. So that's one way to think about it,” he said. “Unlike lentiviral integration, we can redose the lipid nanoparticle in patients. … By repeat dosing, you can treat the patient's cancer without the risk of oncogenesis via integration. So, there are a lot of ways to think about this. I think we are still in very early days.” Their next steps include completing additional experiments this year to select the final design, further optimizing the nanoparticle, the circRNA and the CAR, and nominating a development candidate in early 2027, with initial indications in hematologic cancers and potential extensions into autoimmunity (29th Annu Meet Am Soc Gen Cell Ther (ASGCT) (May 11-16, Boston) 2026).·13 min sittenStrand validates circRNA in LNP/in vivo CAR-T. Circio validates circRNA in AAV/gene therapy. Both indicate that the field is moving in the same direction. Strand shows that circRNA can function very strongly in LNP/in vivo CAR-T. Circio shows that circRNA can greatly improve AAV gene therapy. Together, they make the sector more attractive for Big Pharma.
- ·38 min sittenStop sharing old analyses and data that we've known since February! It's super awkward. ASGCT's presentations have for Circio meant a focus on reduced dosage, thereby improved safety and better economics, which is clearly the big problem with classic mRNA and what Big Pharma craves. But also shown that circVec can potentially be used in all types of tissue/body parts. That they now also have an "ongoing muscle program", as the 4th area, is super exciting. 💰 Now it's just about building relationships and publishing even more, but fortunately we have Erik Wiklund who is a true world champion in that field.
- 25 min sitten25 min sittenTämä julkaisu on poistettu.·25 min sittenI also don't have the energy to read up on it, just like sigpig, so if someone would serve it all to me on a silver platter? Because we REALLY don't have the energy to do things ourselves.
- ·44 min sittenAI finds increased mention in social media and LinkedIn after oral presentation. Also a bit interesting that the topic of conversation around Circio changes character a bit. From AI: There are now clear signs of increasing international visibility around Circio Holding ASA after the ASGCT presentation. Most important new developments: * BiotechTV-interview from ASGCT gets noticeably more spread than previous Circio mentions. CEO Erik Wiklund highlights: * up to 50x increased expression, * lower dosage requirements, * and expansion towards eye, CNS and in vivo CAR-T. * Several biotech profiles on LinkedIn now refer to circRNA as "next-generation therapeutic format", and Circio is mentioned in the same conversations as broader RNA and AAV optimization trends. * It seems that the presentation especially arouses interest because the data addresses some of the biggest challenges in AAV gene therapy: * toxicity at high doses, * production costs, * and insufficient expression. * Analyst Group continues to be among the most positive external voices. They now highlight: * oral selection as third-party validation, * stronger partner relevance, * and that ASGCT can act as a catalyst for licensing dialogues. * It is also noted that Circio now mentions: * existing partnerships, * funding of ~$35M, * and several programs in parallel, which gives a more "platform company" feel than before. * Activity on LinkedIn seems to have increased further since yesterday: * higher engagement on CEO posts, * more biotech-related reposts, * and more international exposure than normal for the company. * There is still relatively little retail hype on open investor forums compared to how much professional discussion is now appearing. It is actually quite interesting, because the attention seems more driven by: * technology, * scientific relevance, * and industrial application, than pure speculation. The most interesting signal right now is perhaps that the discussion gradually shifts from: * "can the technology work?" to: * "how broadly can this be applied and who can become a partner?"·3 min sittenThe BiotechTV interview is more important than usual retail coverage. This is not just a Norwegian stock forum talking to itself. BiotechTV covers American biotech and the ASGCT community. When Circio is featured there, the company becomes more visible to a community that actually understands AAV, RNA, gene therapy, and partner logic.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 55 | - | - | ||
| 3 950 | - | - | ||
| 50 | - | - | ||
| 10 000 | - | - | ||
| 9 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
31 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 min sittenThe ASGCT presentations have, in my opinion, more clearly moved the Circio case from "high expression" to what Big Pharma actually cares most about: significant dose reduction, better safety margin, and lower treatment cost in AAV gene therapy.
- 34 min sitten34 min sittenThe power of circular RNA. More circular RNA at ASGCT, abstract https://distribution.us.m-anage.com/from.storage?image=Kn0KAtCjscVNEYTvg0_NVyDmqYH4nOiZ0PoDsZiXFgrGMRTL5OIsNl3NVnleDe7r0 , Strand Therapeutics on X https://x.com/StrandTx/status/2055271986285117628?s=20 Summary: Boston biotech Strand Therapeutics Inc. is also a pioneer developing circRNA based technologies for the in vivo programming of CAR Ts. At ASGCT, the company presented data of their STX-005 strategy for autoimmune disease and hematological malignancies, including refractory autoimmune conditions, lymphomas and multiple myelomas. “We are trying to convert this therapy, recreate all the wonderful clinical efficacy in an off the shelf format using a lipid nanoparticle and a circular RNA inside the lipid nanoparticle that expresses the chimeric antigen receptor,” Tasuku Kitada told BioWorld. Kitada is the co-founder, board director, president, and head of R&D at Strand Therapeutics. STX-005 combines three layers of engineering, the delivery vector, the circular RNA and the CAR receptor itself. However, this design includes a novel component that solves of target activation. The foundation is a targeted LNP capable of recognizing and transfecting CD8 lymphocytes inside the body. Inside the LNP travels a circular RNA that expresses the CAR. This RNA is deeply optimized to increase translation about tenfold compared with natural sequences and uses codon optimization specifically for circRNA. The goal is to achieve high and durable protein levels without relying on integrative vectors. In addition, STX-005 incorporates a Signallock system based on endogenous microRNA sensors. The circRNA contains sequences that allow microRNAs to modulate it or enable unwanted cells to degrade it, while in T cells it remains intact and functional. This restricts CAR expression to lymphocytes and prevents activity in tissues such as liver, lung or heart. “We are using what we call our Signallock technology, that technology where the signal is the key, and we're blocking it so that only when the signal is delivered to the target cells, the immune cells, we unlock the signal and express protein. And the reason we're doing that, for instance for chimeric antigen receptor T cell therapy, is that you want to express it in the T cells,” Kitada explained. “And the reason that's important is that if you think about a potential immune response that you can trigger inside the patient's body against the chimeric antigen receptors, you really want to limit the protein expression to the cells where you need to express it,” he remarked. The design uses costimulatory and activation domains that increase the efficacy of the CAR. “Our circular RNA is longer lasting because it's circular and because of all the optimizations. … However, it's still transient. It eventually goes away and gets degraded. So, you can optimize what's called the costimulatory domain or activation domain. And there are a lot of engineering tricks that you can incorporate into the chimeric antigen receptor so that it's optimal for this kind of transient mRNA or circular RNA based expression approach,” he said. The results show clear improvements in every model evaluated. In resting human T cells, the optimized circRNAs increase CAR expression sixfold on day 1 and twofold on day 7. The redesigned CAR also performs better, showing a fivefold increase in surface expression after antigen contact and a similar boost in cytotoxic activity in vitro. In vivo, the targeted LNP efficiently delivers the payload, reaching up to 90 percent expression in humanized mice and causing up to 90 percent B cell depletion with a single dose. The Signallock system also works as intended, keeping expression restricted to T cells. In non-human primates, two intravenous doses lead to up to 98 percent B cell depletion in blood, spleen, and lymph nodes. Overall, the combination of the optimized circRNA, the targeted LNP and the CAR design adapted for transient expression produces strong activity across models while maintaining cell type specificity. “You want that transient but deep depletion of the B cells. … The pathogenic B cells are depleted, and then you recover, and you don't have any risk of cancer. So that's one way to think about it,” he said. “Unlike lentiviral integration, we can redose the lipid nanoparticle in patients. … By repeat dosing, you can treat the patient's cancer without the risk of oncogenesis via integration. So, there are a lot of ways to think about this. I think we are still in very early days.” Their next steps include completing additional experiments this year to select the final design, further optimizing the nanoparticle, the circRNA and the CAR, and nominating a development candidate in early 2027, with initial indications in hematologic cancers and potential extensions into autoimmunity (29th Annu Meet Am Soc Gen Cell Ther (ASGCT) (May 11-16, Boston) 2026).·13 min sittenStrand validates circRNA in LNP/in vivo CAR-T. Circio validates circRNA in AAV/gene therapy. Both indicate that the field is moving in the same direction. Strand shows that circRNA can function very strongly in LNP/in vivo CAR-T. Circio shows that circRNA can greatly improve AAV gene therapy. Together, they make the sector more attractive for Big Pharma.
- ·38 min sittenStop sharing old analyses and data that we've known since February! It's super awkward. ASGCT's presentations have for Circio meant a focus on reduced dosage, thereby improved safety and better economics, which is clearly the big problem with classic mRNA and what Big Pharma craves. But also shown that circVec can potentially be used in all types of tissue/body parts. That they now also have an "ongoing muscle program", as the 4th area, is super exciting. 💰 Now it's just about building relationships and publishing even more, but fortunately we have Erik Wiklund who is a true world champion in that field.
- 25 min sitten25 min sittenTämä julkaisu on poistettu.·25 min sittenI also don't have the energy to read up on it, just like sigpig, so if someone would serve it all to me on a silver platter? Because we REALLY don't have the energy to do things ourselves.
- ·44 min sittenAI finds increased mention in social media and LinkedIn after oral presentation. Also a bit interesting that the topic of conversation around Circio changes character a bit. From AI: There are now clear signs of increasing international visibility around Circio Holding ASA after the ASGCT presentation. Most important new developments: * BiotechTV-interview from ASGCT gets noticeably more spread than previous Circio mentions. CEO Erik Wiklund highlights: * up to 50x increased expression, * lower dosage requirements, * and expansion towards eye, CNS and in vivo CAR-T. * Several biotech profiles on LinkedIn now refer to circRNA as "next-generation therapeutic format", and Circio is mentioned in the same conversations as broader RNA and AAV optimization trends. * It seems that the presentation especially arouses interest because the data addresses some of the biggest challenges in AAV gene therapy: * toxicity at high doses, * production costs, * and insufficient expression. * Analyst Group continues to be among the most positive external voices. They now highlight: * oral selection as third-party validation, * stronger partner relevance, * and that ASGCT can act as a catalyst for licensing dialogues. * It is also noted that Circio now mentions: * existing partnerships, * funding of ~$35M, * and several programs in parallel, which gives a more "platform company" feel than before. * Activity on LinkedIn seems to have increased further since yesterday: * higher engagement on CEO posts, * more biotech-related reposts, * and more international exposure than normal for the company. * There is still relatively little retail hype on open investor forums compared to how much professional discussion is now appearing. It is actually quite interesting, because the attention seems more driven by: * technology, * scientific relevance, * and industrial application, than pure speculation. The most interesting signal right now is perhaps that the discussion gradually shifts from: * "can the technology work?" to: * "how broadly can this be applied and who can become a partner?"·3 min sittenThe BiotechTV interview is more important than usual retail coverage. This is not just a Norwegian stock forum talking to itself. BiotechTV covers American biotech and the ASGCT community. When Circio is featured there, the company becomes more visible to a community that actually understands AAV, RNA, gene therapy, and partner logic.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 55 | - | - | ||
| 3 950 | - | - | ||
| 50 | - | - | ||
| 10 000 | - | - | ||
| 9 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt